Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?

Institut Paoli-Calmettes

Status: Unknown

Conditions: Lymphoma, B-Cell

Treatments: Procedure: Autograft

Study type: Observational

Funder types: Other

Identifiers

NCT03681938

ALERT-IPC 2017-015

Details and patient eligibility

About

The autograft of patients with prognostically unfavourable B-cells lymphoma cells in first remission remains controversial, in particular since the association of Rituximab with chemotherapy. Even though many randomized and non-randomized studies have been conducted, their is still no standard procedure . Recently, the use of early TEP (positron emission topography) answer, after 2 in 3 cures of chemotherapy allowed to select the poor-responder patients who remain candidate to autograft in front-line. Nevertheless, in good-responder patients, the benefits of an intensification therapy ins term of long-lasting disease control remains discussion.

This institutional retrospective study aims at comparing the outcome of early metabolic responder patients who received an intensification treatment to those who received a standard chemotherapy.

Enrollment: 183 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with High Risk Big B Cells Lymphoma
• Age > 18 years

Exclusion criteria

• Not applicable

Trial design

183 participants in 2 patient groups

Intensification treatment: Autograft

Treatment:

Procedure: Autograft

Standard chemotherapy (without autograft)